© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
This OncView program features content experts who share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.
March 22nd 2022
David Aggen, MD, PhD discusses trends in renal cell carcinoma (RCC) incidence.
Arnab Basu, MD, MPH, FACP provides an overview of RCC histologies.
March 30th 2022
Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.
Mehmet Asim Bilen, MD comments on the prognosis of patients with metastatic RCC and how recent advances have improved outcomes.
David Aggen, MD, PhD reviews how he currently approaches biomarker testing in patients with RCC.
Mehmet Asim Bilen, MD weighs in on various biomarker testing methodologies, sample considerations, and emerging data on novel biomarkers.
Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.
Chung-Han Lee, MD, PhD discusses how genetic mutations inform patient prognosis and decision-making for patients with kidney cancer.
April 18th 2022
Robert Alter, MD compares older, single-agent first line therapies for patients with metastatic clear cell RCC.
David Aggen, MD, PhD touches on the availability of newer first-line combination treatment options for metastatic disease.